Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE
(Thomson Reuters ONE) -
* Sole source request will allow transition toward long-term stockpiling of
Bavarian Nordic's smallpox vaccine
COPENHAGEN, Denmark, June 16, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
today announced notification from the Biomedical Advanced Research and
Development Authority (BARDA) that a request for proposal (RFP) will be issued
for the procurement of lyophilized IMVAMUNE(®).
As cited in the formal notification: "The Department of Health and Human
Services (HHS), Office of the Assistant Secretary for Preparedness and Response
(ASPR), Biomedical Advanced Research and Development Authority (BARDA) and
Acquisition Contracts Management and Grants (AMCG) intend to use other than full
and open competition to award a sole source contract to Bavarian Nordic, A/S.
for procurement of lyophilized IMVAMUNE(®), a lyophilized smallpox vaccine."
"We are very happy to see this announcement from BARDA. This initial request,
which is in line with our expectations, will allow us to begin the transition
from our liquid-frozen formulation, to freeze-dried IMVAMUNE. The long term
stability of this new formulation will allow the U.S. Government to fulfill
their stated goal of protecting a large, at risk, population," said Paul
Chaplin, President and CEO of Bavarian Nordic. "For more than a decade we have
been proud to partner with the U.S. government and assist with their
biopreparedness. We remain ready to do so and look forward to continuing our
relationship well into the future."
The link to the full request can be found here:
https://www.fbo.gov/index?s=opportunity&mode=form&id=5a9a035b917210ff0025c05226d
bdb62&tab=core&_cview=0.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities, and a vaccine for the prevention and
treatment of HPV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such forward-looking
statements are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made, except as
required by law.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Company Announcement no. 17 / 2017
2017-17-en:
http://hugin.info/100065/R/2113738/804119.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 16.06.2017 - 09:27 Uhr
Sprache: Deutsch
News-ID 548289
Anzahl Zeichen: 4954
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
